

VPA10774/069/001

Prinocate 80 mg/8 mg spot-on solution for large cats

Variation	Summary	Date
Vet - F.II.c.1 z)	VRA-R - Vet - F.II.c.1 z) - - Vet - F.II.c.1 z) - Change in the specification parameters and/or limits of an excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	05/05/26
Vet - B3 a)	VNRA - Vet - B3 a) - - Vet - B3 a) - Changes to the quality part of the dossier - Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for importation, manufacturer responsible for batch release, site where batch control takes place, or supplier of (1) a starting material for an active substance, (2) a reagent or (3) an excipient (when mentioned in the dossier)	23/04/26
Vet - C1	VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	31/03/26
Vet - B12 a)	VNRA - Vet - B12 a) - - Vet - B12 a) - Minor changes:— to an approved test procedure — for active substance or a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for the finished product;— for an excipient	16/07/25
Vet - B3 a)	VNRA - Vet - B3 a) - - Vet - B3 a) - Changes to the quality part of the dossier - Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for importation, manufacturer responsible for batch release, site where batch control takes place, or supplier of (1) a starting material for an active substance, (2) a reagent or (3) an excipient (when mentioned in the dossier)	07/07/25
Vet - A1 e)	VNRA - Vet - A1 e) - - Vet - A1 e) Administrative changes - Change in the name or address of a manufacturer or importer of the finished product (including batch release or quality control testing sites)	07/07/25
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	10/06/25
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or	10/06/25

	intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	13/02/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	19/03/24
Vet - B12 c)	VNRA - Vet - B12 c) - c) Minor changes to an approved test procedure for an in-process test - B12 c) Changes to the quality part of the dossier: Minor changes — to an approved test procedure for an in-process test — for active substance; — for the finished product	01/03/24
Vet - B44(Do not use)	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	13/02/24
Vet - F.II.f.1 a) 1.	VRA-R - Vet - F.II.f.1 a) 1. - a) Extension of the shelf life of the finished product 1. As packaged for sale (supported by real time data) - F.II.f.1 a) 1. Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the	19/12/23

	finished product - As packaged for sale (supported by real time data)	
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	03/03/23
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	03/03/23